TG Therapeutics (TGTX) to Release Earnings on Monday

TG Therapeutics (NASDAQ:TGTX - Get Free Report) is set to announce its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. TG Therapeutics's revenue was up 357.0% on a year-over-year basis. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $1.84 during trading hours on Friday, hitting $26.90. The stock had a trading volume of 5,726,750 shares, compared to its average volume of 3,619,056. The company has a 50 day simple moving average of $23.51 and a two-hundred day simple moving average of $20.01. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 44.10 and a beta of 2.21. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. TG Therapeutics has a one year low of $9.81 and a one year high of $26.99.

Analyst Ratings Changes

Several research firms recently issued reports on TGTX. HC Wainwright reissued a "buy" rating and set a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.33.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.